Skip to main content
Graphical abstract for Tsukamoto et al., Targeting cap1 RNA methyltransferases as an antiviral strategy, Cell Chemical Biology (2023)

Publication

Review on new antiviral strategy now online

The review publication of Yuta Tsukamoto et al. is now available in the current issue of Cell Chemical Biology. Based on his latest Science paper, Yuta Tsukamoto now highlights the importance and potential of “Targeting cap1 RNA methyltransferases as an antiviral strategy”. He and his co-authors outline the game-changing options in the treatment of viral infections.


Publication

Tsukamoto Y, Igarashi M, Kato H.
Targeting cap1 RNA methyltransferases as an antiviral strategy.
Cell Chem Biol. 2023 Dec 5:S2451-9456(23)00426-9.
doi: 10.1016/j.chembiol.2023.11.011.
Epub ahead of print. PMID: 38091983.

Related news

The human P2X4 receptor

Publication

A starting point for the development of new pain and cancer drugs

—The human P2X4 receptor plays an important role in chronic pain, inflammation and some types of cancer. Researchers at the University of Bonn and the University Hospital Bonn (UKB) have now discovered a mechanism that can inhibit this receptor. The results were recently published in the scientific journal Nature Communications and open up a pathway for the development of new drugs. A study carried out by the University of Bonn and the University Hospital Bonn throws light on how P2X2 can be inhibited. The results have recently been published in Nature Communications.
View entry
Kato research group

Publication

Ominous false alarm in the kidney

—Bonn researchers have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction. In cooperation with Nanyang Technological University Singapore and the University Hospital Würzburg, among others, the study provides an explanation for how a point mutation in the immune receptor RIG-I transforms the body's defense system into a self-destructive force and causes severe organ-specific autoimmune diseases. The results have now been published in the journal Science Immunology.
View entry
News_Proebstel

Publication

Unique immune signatures to distinguish MOGAD from MS

—Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body’s immune system mistakenly attacks the protective myelin sheath of nerve fibers in the central nervous system. Although MOGAD induces symptoms similar to multiple sclerosis (MS), its underlying biology appears to be fundamentally different. Understanding these distinctions is crucial for developing effective, disease-specific treatments. A new international study now sheds light on these immune differences.
View entry

Back to the news overview